Zhejiang Doer Biologics Co., Ltd.
PrivateLast Round
M&A
Apr 27, 2021
Est. Valuation
$99.65M
Total Funding Raised
$22.29M
Company Overview
Zhejiang Doer Biologics Co., Ltd. operates in Healthcare & Life Sciences and is based in Hangzhou. Its latest recorded funding round was a Series A Extension round in November 2020.
Zhejiang Doer Biologics Co., Ltd. is a biopharmaceutical company that focuses on the discovery and development of multi-domain based multi-specific biotherapeutics to address unmet medical needs in the field of metabolic diseases and cancers.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Zhejiang Doer Biologics Co., Ltd. Comparables
Compare Zhejiang Doer Biologics Co., Ltd. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Gmax Biopharm | 79% | |
| Sciwind Biosciences | 78% | |
| 89bio, Inc. | 77% |
For institutional investors. Book with your work email.
Zhejiang Doer Biologics Co., Ltd. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| M&A | Apr 27, 2021 | ||||
| Series A Extension | Nov 2, 2020 | ||||
| Series A | Feb 13, 2019 | ||||
| Corporate Funding | Jul 30, 2016 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Zhejiang Doer Biologics Co., Ltd. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Zhejiang Sino Wisdom Investment Management | Series A Extension |
| Kaitai Capital | Series A, Series A Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 6, 2025
Monthly visitors increased 1062% MoM, reaching 988.
- Jul 30, 2016
Raised $3M in a corporate funding round.
For institutional investors. Book with your work email.
Zhejiang Doer Biologics Co., Ltd. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Zhejiang Doer Biologics Co., Ltd.'s valuation, stock price, and market status.
Is Zhejiang Doer Biologics Co., Ltd. a public or private company?
Zhejiang Doer Biologics Co., Ltd. is a private company.
What is the current stock price of Zhejiang Doer Biologics Co., Ltd.?
Zhejiang Doer Biologics Co., Ltd. is a private company, so its shares have no public market price. Caplight tracks Zhejiang Doer Biologics Co., Ltd.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Zhejiang Doer Biologics Co., Ltd. worth (valuation)?
Zhejiang Doer Biologics Co., Ltd.'s valuation is estimated at $99.7M based on funding round data.
Can I buy Zhejiang Doer Biologics Co., Ltd. stock?
Zhejiang Doer Biologics Co., Ltd. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Zhejiang Doer Biologics Co., Ltd.'s last funding round?
Zhejiang Doer Biologics Co., Ltd.'s most recent funding round was M&A on April 27, 2021.
Who are the main investors in Zhejiang Doer Biologics Co., Ltd.?
Key investors in Zhejiang Doer Biologics Co., Ltd. include Zhejiang Sino Wisdom Investment Management.
Will Zhejiang Doer Biologics Co., Ltd. IPO soon?
No public IPO plans have been announced for Zhejiang Doer Biologics Co., Ltd..
How can I track Zhejiang Doer Biologics Co., Ltd. secondary market activity?
Caplight tracks bids, offers, and trades in Zhejiang Doer Biologics Co., Ltd.'s shares on secondary markets.